Effectiveness of zinc acetate hydrate supplementation for kidney outcomes in chronic kidney disease patients with hypozincemia - ZAK-CKD Study

Itano Seiji0 个研究点目标入组 200 人开始时间: 2021年8月27日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1) 20 years or older
•2) Patient whose most recent clinical tests performed within 12 weeks prior to enrollment meet all of the following criteria
•eGFR less than 60 ml/min/1.73 m2
•serum zinc level less than 60 micro g/dl
•3) Patient who provide written informed consent

•1) Patient with a serum copper concentration of less than 60 micro g/dl on the most recent laboratory tests performed within 12 weeks prior to enrollment
•2) Patient who continuously receives hemodialysis and peritoneal dialysis
•3) Patient with kidney transplantation
•4) Patient with active cancer, and receiving antineoplastic agent
•5) Patient with a history of upper gastrointestinal resection
•6) Patient with a history of allergy or anaphylaxis of the Zinc-containing preparation
•7) Patient who receives the Zinc-containing preparation or the Zinc-containing supplement within 4 weeks prior to enrollment
•8) Patient who are pregnant or breastfeeding
•9) Patient deemed ineligible for the study by the principal investigator or sub-investigator

发起方

Itano Seiji